Castle Biosciences CSTL Non-Dermatologic — NET REVENUES
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Castle Biosciences in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Castle Biosciences’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Castle Biosciences's non-dermatologic — net revenues.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Castle Biosciences's non-dermatologic — NET REVENUES?
- Castle Biosciences (CSTL) reported non-dermatologic — NET REVENUES of $42.57M in Q1 2026.
- How has Castle Biosciences's non-dermatologic — NET REVENUES changed year-over-year?
- Castle Biosciences's non-dermatologic — NET REVENUES increased by 70.1% year-over-year, from $25.03M to $42.57M.
- What is the long-term trend for Castle Biosciences's non-dermatologic — NET REVENUES?
- Over 3 years (2022 to 2025), Castle Biosciences's non-dermatologic — NET REVENUES has grown at a 118.7% compound annual growth rate (CAGR), from $12.23M to $127.86M.
- What does non-dermatologic — NET REVENUES mean?
- This metric represents the total net revenue generated from diagnostic products and services that fall outside of the company's core dermatological cancer portfolio. It tracks the commercial performance and market adoption of the company's diversification efforts into other therapeutic or diagnostic areas. Monitoring this revenue stream helps investors assess the company's ability to expand its clinical utility beyond its primary market segment.